UBS raised the firm’s price target on Amicus (FOLD) to $22 from $21 and keeps a Buy rating on the shares. While 2025 guidance for Pompe disease was lowered, the long-term is on track and the Dimerix deal is a positive, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Amicus Positioned for Growth with Strategic Licensing and Promising FSGS Treatment
- Amicus Therapeutics Reports Strong Q1 2025 Growth
- Amicus’s Strategic Positioning and Growth Potential Justify Buy Rating Despite Revenue Misses
- Amicus Therapeutics’ Earnings Call Highlights Growth and Strategic Moves
- Amicus lowers FY25 total revenue growth view 15%-22% from 17%-24%